دورية أكاديمية
أعرض في EDS

Serum Interleukin 6 Level is Associated With Overall Survival and Treatment Response in Gastric and Gastroesophageal Junction Cancer.

التفاصيل البيبلوغرافية
العنوان: Serum Interleukin 6 Level is Associated With Overall Survival and Treatment Response in Gastric and Gastroesophageal Junction Cancer.
المؤلفون: Karalis JD; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX., Ju MR; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX., Yoon LY; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX., Castro-Dubon EC; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX., Reznik SI; Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX., Hammer STG; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX., Porembka MR; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX., Wang SC; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX.
المصدر: Annals of surgery [Ann Surg] 2023 Dec 01; Vol. 278 (6), pp. 918-924. Date of Electronic Publication: 2023 Jul 14.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0372354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-1140 (Electronic) Linking ISSN: 00034932 NLM ISO Abbreviation: Ann Surg Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Stomach Neoplasms*/pathology , Esophageal Neoplasms*, Humans ; Interleukin-6 ; Esophagogastric Junction/pathology ; Neoadjuvant Therapy ; Biomarkers
مستخلص: Objective: To identify novel prognostic and predictive biomarkers for gastric and gastroesophageal junction (G+GEJ) adenocarcinoma.
Background: There are few biomarkers to guide treatment for G+GEJ. The systemic inflammatory response of G+GEJ patients is associated with survival. In this study, we evaluated the relationship of circulating serum cytokine levels with overall survival (OS) and pathologic tumor regression grade (TRG) in G+GEJ patients.
Patients and Methods: We queried the UT Southwestern gastric cancer biobank to identify consecutive patients diagnosed with G+GEJ from 2016 to 2022; these patients had pretreatment serum collected at diagnosis. For patients who received neoadjuvant therapy, an additional serum sample was collected immediately before surgical resection. An unbiased screen of 17 cytokines was measured in a discovery cohort. A multivariable Cox proportional hazards model was used to assess the association of cytokine concentration with OS. Findings were validated in additional patients. In patients who received neoadjuvant therapy, we assessed whether the change in interleukin 6 (IL-6) after therapy was associated with TRG.
Results: Sixty-seven patients were included in the discovery cohort, and IL-6 was the only pretreatment cytokine associated with OS; this was validated in 134 other patients (hazard ratio: 1.012 per 1 pg/mL increase, 95% CI: 1.006-1.019, P = 0.0002). Patients in the top tercile of IL-6 level had worse median OS (10.6 months) compared with patients in the intermediate (17.4 months) and bottom tercile (35.8 months, P < 0.0001). Among patients who underwent neoadjuvant therapy (n = 50), an unchanged or decrease in IL-6 level from pretreatment to posttreatment, had a sensitivity and specificity of 80% for predicting complete or near-complete pathologic tumor regression (TRG 0-1).
Conclusions: Pretreatment serum level of IL-6 is a promising prognostic biomarker for G+GEJ patients. Comparing pre and post-neoadjuvant IL-6 levels may predict pathologic response to neoadjuvant therapy.
Competing Interests: J.D.K. holds a Physician-Scientist Institutional Award from the Burroughs Wellcome Fund (Award no. 1018897). M.R.P. is a Dedman Family Scholar in Clinical Care. S.C.W. is a Disease Oriented Clinical Scholar at UT Southwestern. The authors report no conflicts of interest.
(Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
References: Cardoso R, Coburn N, Seevaratnam R, et al. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. Gastric Cancer. 2012;15(suppl 1):19–26.
Hasegawa S, Yoshikawa T, Shirai J, et al. A prospective validation study to diagnose serosal invasion and nodal metastases of gastric cancer by multidetector-row CT. Ann Surg Oncol. 2013;20:2016–2022.
Bentrem D, Gerdes H, Tang L, et al. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol. 2007;14:1853–1859.
Ju MR, Karalis JD, Blackwell JM, et al. Inaccurate clinical stage is common for gastric adenocarcinoma and is associated with undertreatment and worse outcomes. Ann Surg Oncol. 2021;28:2831–2843.
Ju MR, Karalis JD, Wang SC, et al. ASO author reflections: real-world clinical staging failures of presumed early gastric cancers and their negative impact on patient outcomes. Ann Surg. Oncol. 2021;28:2844–2845.
Sandø AD, Fougner R, Grønbech JE, et al. The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study. World J Surg Oncol. 2021;19:212.
Ng CS, Husband JES, Macvicar ADL, et al. Correlation of CT with histopathological findings in patients with gastric and gastro-oesophageal carcinomas following neoadjuvant chemotherapy. Clin Radiol. 1998;53:422–427.
Hallinan JTPD, Venkatesh SK. Gastric carcinoma: imaging diagnosis, staging and assessment of treatment response. Cancer Imaging. 2013;13:212.
Tsujimoto H, Ono S, Ichikura T, et al. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes? Gastric Cancer. 2010;13:212–221.
Wang SC, Chou JF, Strong VE, et al. Pretreatment neutrophil to lymphocyte ratio independently predicts disease-specific survival in resectable gastroesophageal junction and gastric adenocarcinoma. Ann Surg. 2016;263:292–297.
Nakauchi M, Court CM, Tang LH, et al. Validation of the Memorial Sloan Kettering Gastric Cancer post-resection survival nomogram: does it stand the test of time? J Am Coll Surg. 2022;235:294–304.
Lin W-W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117:1175–1183.
Ryan R, Gibbons D, Hyland JMP, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47:141–146.
Lombardi PM, Mazzola M, Achilli P, et al. Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a single‐center experience. J Surg Oncol. 2021;123:923–931.
Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37:3392–3400.
Nassour I, Fullington H, Hynan LS, et al. The yield of staging laparoscopy in gastric cancer is affected by racial and ethnic differences in disease presentation. Ann Surg Oncol. 2017;24:1787–1794.
Chen Y-C, Fang WL, Wang RF, et al. Clinicopathological variation of Lauren classification in gastric cancer. Pathol Oncol Res. 2016;22:197–202.
Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.
Cheong J-H, Wang SC, Park S, et al. Development and validation of a prognostic and predictive 32-gene signature for gastric cancer. Nat Commun. 2022;13:774.
Park S, Karalis JD, Hong C, et al. ACTA2 expression predicts survival and is associated with response to immune checkpoint inhibitors in gastric cancer. Clin Cancer Res. 2022;29:1077–1085.
Hacker UT, Hasenclever D, Baber R, et al. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial. Ann Oncol. 2022;33:685–692.
Demirelli B, Babacan NA, Ercelep Ö, et al. Modified Glasgow prognostic score, prognostic nutritional index and ECOG performance score predicts survival better than sarcopenia, cachexia and some inflammatory indices in metastatic gastric cancer. Nutr Cancer. 2021;73:230–238.
Tokuyama N, Takegawa N, Nishikawa M, et al. Pretreatment Glasgow prognostic score as a predictor of outcomes in nivolumab-treated patients with advanced gastric cancer. PLoS One. 2021;16:e0247645.
Liao WC, Lin JT, Wu CY, et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res. 2008;14:428–434.
Kim D-K, Oh SY, Kwon HC, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009;9:155.
Tsai S, George B, Wittmann D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann Surg. 2020;271:740–747.
Humphris JL, Chang DK, Johns AL, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713–1722.
Gulhati P, Yin J, Pederson L, et al. Threshold change in CEA as a predictor of non-progression to first-line systemic therapy in metastatic colorectal cancer patients with elevated CEA. J Nat Cancer Inst. 2020;112:1127–1136.
Vainer N, Dehlendorff C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget. 2018;9:29820–29841.
Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234–248.
Rossi J-F, Lu ZY, Jourdan M, et al. Interleukin-6 as a therapeutic target. Clin Cancer Res. 2015;21:1248–1257.
Guo Y, Xu F, Lu T, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904–910.
Zhou Q-X, Jiang XM, Wang ZD, et al. Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis. Med Oncol. 2015;32:105.
Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103–113.
Spicer JD, McDonald B, Cools-Lartigue JJ, et al. Neutrophils promote liver metastasis via Mac-1–mediated interactions with circulating tumor cellsneutrophil/tumor cell adhesion promotes metastasis. Cancer Res. 2012;72:3919–3927.
Cools-Lartigue J, Spicer J, McDonald B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123:3446–3458.
Rayes RF, Mouhanna JG, Nicolau I, et al. Primary tumors induce neutrophil extracellular traps with targetable metastasis-promoting effects. JCI Insight. 2019;4:e128008.
Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Eng J Med. 2005;353:2654–2666.
Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Eng J Med. 2003;348:203–213.
المشرفين على المادة: 0 (Interleukin-6)
0 (Biomarkers)
SCR Disease Name: Adenocarcinoma Of Esophagus
تواريخ الأحداث: Date Created: 20230714 Date Completed: 20231109 Latest Revision: 20231122
رمز التحديث: 20231122
DOI: 10.1097/SLA.0000000000005997
PMID: 37450705
قاعدة البيانات: MEDLINE
الوصف
تدمد:1528-1140
DOI:10.1097/SLA.0000000000005997